Jason Lettmann, ALX Oncology CEO (Lightstone Ventures)
October 3, 2023 07:34 AM EDTUpdated 11:24 AM
R&D

Up­dat­ed: In turn­around, ALX On­col­o­gy’s CD47 block­er shows ef­fi­ca­cy in gas­tric can­cer tri­al

Lei Lei Wu

News Reporter

Don’t write off CD47 just yet.

ALX On­col­o­gy said that 52% of gas­tric can­cer pa­tients who re­ceived its an­ti-CD47 drug evor­pacept in com­bi­na­tion with a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

In sur­prise, study sug­gests Covid mR­NA vac­cines may boost can­cer im­munother­a­py ef­fi­ca­cy

Pfiz­er tees up Phase 3 test in weight man­age­ment — but in an un­ex­pect­ed area

Ex-Kite lead­ers step in at Kyver­na as CEO ex­its af­ter land­ing year's sec­ond-biggest IPO

BioN­Tech rolls out Phase 2 lung can­cer da­ta as VEGF bis­pecifics take cen­ter stage

Im­mat­ics los­es Bris­tol My­er­s' sup­port on Phase 1 bis­pe­cif­ic T cell en­gager

sponsored

Break­ing down si­los with a new quan­ti­ta­tive ap­proach to drug de­vel­op­ment

A service from the Financial Times